NasdaqGS:EWTXPharmaceuticals
Edgewise Therapeutics (EWTX) Stock Looks Fully Priced After Phase 2 HCM Progress
Edgewise Therapeutics (EWTX) drew fresh investor attention after reporting favorable Phase 2 Part D CIRRUS-HCM data for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy, with results supporting progression to Phase 3 development.
See our latest analysis for Edgewise Therapeutics.
The Phase 2 CIRRUS-HCM update lands at a time when Edgewise Therapeutics has already seen strong momentum, with a 1-month share price return of 12.57% and a year-to-date share price return of...